Evidence map›Paper›PMID 31859241›Full record

ArticleEBioMedicine2020

Ontological analyses reveal clinically-significant clear cell renal cell carcinoma subtypes with convergent evolutionary trajectories into an aggressive type.

Qi Cai, Alana Christie, Satwik Rajaram, Qinbo Zhou, Ellen Araj, Suneetha Chintalapati, Jeffrey Cadeddu, Vitaly Margulis, Ivan Pedrosa, Dinesh Rakheja and 3 more

Erratum issuedAbstract read
In one paragraph

Article in EBioMedicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 37 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

37 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. New developments in existing WHO entities and evolving molecular concepts: The Genitourinary Pathology Society (GUPS) update on renal neoplasia.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2021
    Guideline
  2. Trial
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Determinants of late metastases in renal cell carcinoma.Journal of the National Cancer Institute · 2025
    Article
  9. Article
  10. Preoperative prediction of WHO/ISUP grade of ccRCC using intratumoral and peritumoral habitat imaging: multicenter study.Cancer imaging : the official publication of the International Cancer Imaging Society · 2025
    Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors.

Qi CaiDepartment of Pathology, University of Texas Southwestern Medical Center, Dallas, TX 75390, United States.
Alana ChristieKidney Cancer Program, Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX 75390, United States.
Satwik RajaramDepartment of Bioinformatics, University of Texas Southwestern Medical Center, Dallas, TX 75390, United States.
Qinbo ZhouDepartment of Bioinformatics, University of Texas Southwestern Medical Center, Dallas, TX 75390, United States.
Ellen ArajDepartment of Pathology, University of Texas Southwestern Medical Center, Dallas, TX 75390, United States.
Suneetha ChintalapatiDepartment of Pathology, University of Texas Southwestern Medical Center, Dallas, TX 75390, United States.
Jeffrey CadedduDepartment of Urology, University of Texas Southwestern Medical Center, Dallas, TX 75390, United States; Kidney Cancer Program, Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX 75390, United States.
Vitaly MargulisDepartment of Urology, University of Texas Southwestern Medical Center, Dallas, TX 75390, United States; Kidney Cancer Program, Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX 75390, United States; Institute for Urology and Reproductive Health, Sechenov University, Moscow, Russia.
Ivan PedrosaDepartment of Urology, University of Texas Southwestern Medical Center, Dallas, TX 75390, United States; Department of Radiology, University of Texas Southwestern Medical Center, Dallas, TX 75390, United States; Kidney Cancer Program, Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX 75390, United States.
Dinesh RakhejaDepartment of Pathology, University of Texas Southwestern Medical Center, Dallas, TX 75390, United States; Kidney Cancer Program, Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX 75390, United States.
Renee M McKayKidney Cancer Program, Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX 75390, United States.
James BrugarolasDepartment of Internal Medicine, Hematology-Oncology Division, University of Texas Southwestern Medical Center, Dallas, TX 75390, United States; Kidney Cancer Program, Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX 75390, United States. Electronic address: james.brugarolas@utsouthwestern.edu.
Payal KapurDepartment of Pathology, University of Texas Southwestern Medical Center, Dallas, TX 75390, United States; Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX 75390, United States; Kidney Cancer Program, Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX 75390, United States. Electronic address: payal.kapur@utsouthwestern.edu.

Funding

University of Texas Southwestern Medical Center SPORE in Kidney CancerP50CA196516 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI James Brugarolas · 2016 to 2026
$24.7M
NON-INVASIVE PHYSIOLOGIC PREDICTORS OF AGGRESSIVENESS IN RENAL CELL CARCINOMAR01CA154475 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI PEDROSA, IVAN · 2011 to 2024
$4.3M
NCI NIH HHS P50 CA196516NCI NIH HHS R01 CA154475
6 · The paper itself

Abstract

backgroundClear cell renal cell carcinoma (ccRCC) is a particularly challenging tumor type because of its extensive phenotypic variability as well as intra-tumoral heterogeneity (ITH). Clinically, this complexity has been reduced to a handful of pathological variables such as stage, grade and necrosis, but these variables fail to capture the breadth of the disease. How different phenotypes affect patient prognosis and influence therapeutic response is poorly understood. Extensive ITH illustrates remarkable plasticity, providing a framework to study tumor evolution. While multiregional genomic analyses have shown evolution from an ancient clone that acquires metastatic competency over time, these studies have been conducted agnostic to morphological cues and phenotypic plasticity.

methodsWe established a systematic ontology of ccRCC phenotypic variability by developing a multi-scale framework along three fundamental axes: tumor architecture, cytology and the microenvironment. We defined 33 parameters, which we comprehensively evaluated in 549 consecutive ccRCCs retrospectively. We systematically evaluated the impact of each parameter on patient outcomes, and assessed their contribution through multivariate analyses. We measured therapeutic impact in the context of anti-angiogenic therapies. We applied dimensionality reduction by t-distributed stochastic neighbor embedding (t-SNE) algorithms to tumor architectures for the study of tumor evolution superimposing tumor size and grade vectors. Evolutionary models were refined through empirical analyses of directed evolution of tumor intravascular extensions, and metastatic competency (as determined by tumor reconstitution in a heterologous host).

findingsWe discovered several novel ccRCC phenotypes, developed an integrated taxonomy, and identified features that improve current prognostic models. We identified a subset of ccRCCs refractory to anti-angiogenic therapies. We developed a model of tumor evolution, which revealed converging evolutionary trajectories into an aggressive type.

interpretationThis work serves as a paradigm for deconvoluting tumor complexity and illustrates how morphological analyses can improve our understanding of ccRCC pleiotropy. We identified several subtypes associated with aggressive biology, and differential response to targeted therapies. By analyzing patterns of spatial and temporal co-occurrence, intravascular tumor extensions and metastatic competency, we were able to identify distinct trajectories of convergent phenotypic evolution.

Indexed as

AdultAgedAged, 80 and overAngiogenesis InhibitorsAnimalsCarcinoma, Renal CellDisease-Free SurvivalFemaleGenetic HeterogeneityHumansKidney NeoplasmsMaleMice, Inbred NODMice, SCIDMultivariate AnalysisNeoplasm InvasivenessAngiogenesis InhibitorsAngiogenesis inhibitorsccRCCImmune checkpoint inhibitorsMorphologic heterogeneityPrognosisTKIsTumor evolution

Identifiers

PMID31859241
PMCPMC7000318

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.